Johnson & Johnson wins EU approval to buy Actelion

The European Commission’s Directorate-General for Competition has conditionally cleared pharmaceutical company Johnson & Johnson’s acquisition of Swiss biotechnology company Actelion after a Phase I review, subject to conditions aimed at maintaining competition in the development of insomnia drugs.

Get unlimited access to all Global Competition Review content